Development of alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell derived liver organoids

Zhiwei Feng,Bingrui Zhou,Qizhi Shuai,Yunliang Wei,Ning Jin,Xiaoling Wang,Hong Zhao,Zhizhen Liu,Jun Xu,Jianbing Mu,Jun Xie

DOI: https://doi.org/10.1101/2024.03.10.584291

2024-03-12

Abstract:Alcoholic liver disease (ALD) poses a significant health challenge, demanding comprehensive research efforts to enhance our comprehension and treatment strategies. However, the development of effective treatments is hindered by the limitations of existing liver disease models. Liver organoids, characterized by their cellular complexity and three-dimensional (3D) tissue structure closely resembling the human liver, hold promise as ideal models for liver disease research. In this study, we employ a meticulously designed protocol involving the differentiation of human induced pluripotent stem cells (hiPSCs) into liver organoids. This process incorporates a precise combination of cytokines and small molecule compounds within a 3D culture system to guide the differentiation process. Subsequently, these differentiated liver organoids are subjected to ethanol treatment to induce ALD, thus establishing a disease model. Rigorous assessment through a series of experiments reveals that this model partially replicates key pathological features observed in clinical ALD, including cellular mitochondrial damage, elevated cellular reactive oxygen species (ROS) levels, fatty liver, and hepatocyte necrosis. In addition, this model offers potential utility in screening drugs for ALD treatment. Taken together, the liver organoids model of ALD, derived from hiPSCs differentiation, emerges as an invaluable platform for advancing our understanding and management of ALD in clinical settings.

Cell Biology

What problem does this paper attempt to address?

The main objective of this paper is to develop a liver organoid model derived from human induced pluripotent stem cells (hiPSCs) for the study and drug screening of alcoholic liver disease (ALD). Specifically, the research team designed a detailed protocol to guide the differentiation of hiPSCs into liver organoids by using a precise combination of cytokines and small molecule compounds in a three-dimensional (3D) culture system. These liver organoids were then treated with ethanol to induce ALD, thereby establishing a disease model. This model successfully replicated key pathological features of clinical ALD, including mitochondrial damage in cells, elevated intracellular reactive oxygen species (ROS) levels, fatty liver, and hepatocyte necrosis. Furthermore, the study validated that this model can be used for the screening of therapeutic drugs for ALD, indicating that the hiPSC-derived liver organoid ALD model provides a valuable platform for understanding and managing clinical ALD. In summary, this paper aims to address the limitations of current models in ALD research by developing a liver organoid model that more closely mimics the real human condition, thereby promoting the understanding of ALD and accelerating the process of finding effective treatments.

Development of alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell derived liver organoids

Modeling alcohol-associated liver disease in humans using adipose stromal or stem cell-derived organoids

Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease

A Liver-Chip-based Alcoholic Liver Disease Model Featuring Multi-Non-parenchymal Cells.

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids

Mice Hepatic Organoids for Modeling Nonalcoholic Fatty Liver Disease and Drug Response

A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression

Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System

Advancements in the Alcohol-Associated Liver Disease Model

Liver Organoids: Established Tools for Disease Modeling and Drug Development

Protocol to generate human liver spheroids to study liver fibrosis induced by metabolic stress

Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

A Liver Analog Construct for Use As an Alcoholic Liver Disease Model

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Rhesus Monkey Model Of Liver Disease Reflecting Clinical Disease Progression And Hepatic Gene Expression Analysis

Human Liver Organoid: Modeling Liver Steatosis and Beyond

A decade of liver organoids: Advances in disease modeling

Generation of Fibrotic Liver Organoids Using Hepatocytes, Primary Liver Sinusoidal Endothelial Cells, Hepatic Stellate Cells, and Macrophages

Tissue Engineered Artificial Liver Model Based on Viscoelastic Hyaluronan-Collagen Hydrogel and the Effect of EGCG Intervention on ALD